600196 复星医药
午间休市 12-11 11:29:55
资讯
新帖
简况
复星医药子公司桂林南药膦甲酸钠注射液注册申请获批
财中社 · 12-10 16:55
复星医药子公司桂林南药膦甲酸钠注射液注册申请获批
群益证券：维持复星医药(02196)“买进”评级 目标价26.5港元
智通财经 · 12-10 15:24
群益证券：维持复星医药(02196)“买进”评级 目标价26.5港元
辉瑞恋战减肥药 还惦记上你的猫
经济观察网 · 12-10 10:04
辉瑞恋战减肥药 还惦记上你的猫
复星医药A股和H股分别上涨近4%和近6%
每日经济新闻 · 12-10 09:56
复星医药A股和H股分别上涨近4%和近6%
复星医药(600196.SH)：HLX22联合注射用HLX87获临床试验批准
智通财经 · 12-09 20:09
复星医药(600196.SH)：HLX22联合注射用HLX87获临床试验批准
复星医药旗下耀南药业与辉瑞达成独家合作与许可协议
美股速递 · 12-09 19:56
复星医药旗下耀南药业与辉瑞达成独家合作与许可协议
复星医药最新公告：控股子公司药友制药与辉瑞签订许可协议
证券之星 · 12-09 19:00
复星医药最新公告：控股子公司药友制药与辉瑞签订许可协议
复星医药最新公告：公司多款药品新纳入国家医保目录及商保创新药目录
证券之星 · 12-07
复星医药最新公告：公司多款药品新纳入国家医保目录及商保创新药目录
复星医药2025年A股股票期权激励计划首次授予完成，182名激励对象获授444.64万份期权
中金财经 · 12-04
复星医药2025年A股股票期权激励计划首次授予完成，182名激励对象获授444.64万份期权
复星医药最新公告：控股子公司拟用于治疗晚期恶性实体瘤创新药物FXS887片获临床试验批准于全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市
证券之星 · 12-03
复星医药最新公告：控股子公司拟用于治疗晚期恶性实体瘤创新药物FXS887片获临床试验批准于全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市
复星医药旗下私募基金LP变更，大连金运接替大连融达成新合伙人
中金财经 · 12-03
复星医药旗下私募基金LP变更，大连金运接替大连融达成新合伙人
复星医药（600196）披露选举执行董事议案获股东会通过，12月2日股价下跌0.88%
证券之星 · 12-02
复星医药（600196）披露选举执行董事议案获股东会通过，12月2日股价下跌0.88%
复星医药 - 含肝素钠注射液的药物申请已被NMPA接受
美股速递 · 12-02
复星医药 - 含肝素钠注射液的药物申请已被NMPA接受
复星医药(02196)：刘毅获选举为执行董事
智通财经 · 12-02
复星医药(02196)：刘毅获选举为执行董事
复星医药子公司HLX14药品注册申请获受理
财中社 · 12-02
复星医药子公司HLX14药品注册申请获受理
复星医药子公司肝素钠注射液注册申请获国家药监局受理
财中社 · 12-02
复星医药子公司肝素钠注射液注册申请获国家药监局受理
复星医药(600196.SH)控股子公司HLX37注射液获临床试验批准
智通财经 · 12-01
复星医药(600196.SH)控股子公司HLX37注射液获临床试验批准
复星医药（600196）披露关于召开2025年第二次临时股东会的提示性公告，11月28日股价下跌0.29%
证券之星 · 11-28
复星医药（600196）披露关于召开2025年第二次临时股东会的提示性公告，11月28日股价下跌0.29%
复星医药与睿智医药达成战略合作
人民财讯 · 11-25
复星医药与睿智医药达成战略合作
复星医药(600196.SH)子公司芦沃美替尼片药品注册申请获受理
智通财经 · 11-21
复星医药(600196.SH)子公司芦沃美替尼片药品注册申请获受理
暂无数据
公司概况
公司名称：
上海复星医药(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1998-08-07
主营业务：
上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。
发行价格：
7.15
{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":28.75,"timestamp":1765423795000,"preClose":28.32,"halted":0,"volume":25802045,"delay":0,"changeRate":0.0152,"floatShares":2118000000,"shares":2670000000,"eps":1.2293,"marketStatus":"午间休市","change":0.43,"latestTime":"12-11 11:29:55","open":28.32,"high":29.12,"low":28.27,"amount":743000000,"amplitude":0.03,"askPrice":28.75,"askSize":19,"bidPrice":28.74,"bidSize":81,"shortable":0,"etf":0,"ttmEps":1.2293,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765429200000},"marketStatusCode":3,"adr":0,"adjPreClose":28.32,"symbolType":"stock","openAndCloseTimeList":[[1765416600000,1765423800000],[1765429200000,1765436400000]],"highLimit":31.15,"lowLimit":25.49,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.57,"roa":"--","peRate":23.387294,"roe":"5.3%","epsLYR":1.04,"committee":0.54289,"marketValue":76775000000,"turnoverRate":0.0122,"status":0,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":22.56,"timestamp":1765424775396,"preClose":22.3,"halted":0,"volume":3705810,"delay":0,"premium":"-28.78"},"floatMarketCap":60907000000},"requestUrl":"/m/hq/s/600196/tweets","defaultTab":"tweets","newsList":[{"id":"2590307040","title":"复星医药子公司桂林南药膦甲酸钠注射液注册申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2590307040","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590307040?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:55","pubTimestamp":1765356926,"startTime":"0","endTime":"0","summary":"12月10日，复星医药（600196/02196）发布公告，控股子公司桂林南药股份有限公司的膦甲酸钠注射液药品注册申请已获国家药品监督管理局批准。该药品适应症包括用于治疗艾滋病患者巨细胞病毒性视网膜炎和免疫功能损害患者耐阿昔洛韦单纯疱疹病毒性皮肤粘膜感染。截至2025年11月，公司针对该药品的研发累计投入约为498万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512103587726156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","BK0096","600196","BK0239","BK1515","BK0175","BK0188","BK1593","BK0187","02196","BK0196","BK0183","BK1191","BK0012","BK0028"],"gpt_icon":0},{"id":"2590309455","title":"群益证券：维持复星医药(02196)“买进”评级 目标价26.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590309455","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590309455?lang=zh_cn&edition=full","pubTime":"2025-12-10 15:24","pubTimestamp":1765351440,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，群益证券发布研报称，为反映复星医药大额首付款增厚利润，该行上调盈利预测。该行预计公司2025-2027年分别实现净利润33.2亿元、46.8亿元、47.7亿元，YOY分别+19.8%、+40.8%、+19.1%，EPS分别为1.2元、1.8元、1.8元，对应H股PE分别为16X/11X/11X,H股估值偏低，该行看好其长期发展，维持H股“买进”的投资评级，目标价26.5港元。此外，基于许可产品的年度净销售额达成情况，由辉瑞向药友制药支付至多15.85亿美元的销售里程碑款项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","600196","02196"],"gpt_icon":0},{"id":"2590379472","title":"辉瑞恋战减肥药 还惦记上你的猫","url":"https://stock-news.laohu8.com/highlight/detail?id=2590379472","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590379472?lang=zh_cn&edition=full","pubTime":"2025-12-10 10:04","pubTimestamp":1765332240,"startTime":"0","endTime":"0","summary":"经济观察报记者刘晓诺在减肥药开发路上屡败屡战的辉瑞，再斥重金购买中国创新药。不过，“宇宙第一大药厂”理想的胖友，似乎不只有人类。2025年12月9日，复星医药(600196.SH/02196.HK)公告 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/usstock/20251210/c673094446.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20251210/c673094446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0188","BK0012","BK0028","BK0096","BK0183","BK0187","BK0175","BK0196","BK0060","600196","BK0239"],"gpt_icon":0},{"id":"2590937964","title":"复星医药A股和H股分别上涨近4%和近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590937964","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590937964?lang=zh_cn&edition=full","pubTime":"2025-12-10 09:56","pubTimestamp":1765331812,"startTime":"0","endTime":"0","summary":"复星医药A股和H股分别上涨近4%和近6%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512103587445239.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512103587445239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK1515","02196","BK0060","159982","BK1593","BK0028","BK0196","BK0187","BK0188","BK1191","600196","BK0012","BK0183","BK0175","BK0096","399300"],"gpt_icon":0},{"id":"2590345800","title":"复星医药(600196.SH)：HLX22联合注射用HLX87获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590345800","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590345800?lang=zh_cn&edition=full","pubTime":"2025-12-09 20:09","pubTimestamp":1765282177,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(以下合称“复宏汉霖”)收到国家药品监督管理局关于同意HLX22(即重组人源化抗HER2单克隆抗体注射液)联合注射用HLX87(即靶向HER2抗体偶联药物)于中国境内开展如下临床试验的批准：(1)用于HER2阳性乳腺癌(BC)一线治疗的Ⅱ/Ⅲ期临床试验;(2)用于HER2阳性乳腺癌新辅助治疗(BC neo)的Ⅱ/Ⅲ期临床试验。复宏汉霖拟于条件具备后于中国境内开展上述相关临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0175","BK0012","BK1515","BK0188","BK0239","600196","BK0060","BK0028","BK1593","02196","BK0196","BK0183","BK0096","BK0187"],"gpt_icon":0},{"id":"1170981870","title":"复星医药旗下耀南药业与辉瑞达成独家合作与许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1170981870","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170981870?lang=zh_cn&edition=full","pubTime":"2025-12-09 19:56","pubTimestamp":1765281373,"startTime":"0","endTime":"0","summary":"复星医药旗下耀南药业与辉瑞达成独家合作与许可协议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6692cc092fbadfcafce950a9c4d79e01","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0096","BK0060","BK0188","BK0187","BK0196","BK0183","BK0239","600196","BK0012","BK0028"],"gpt_icon":0},{"id":"2590310434","title":"复星医药最新公告：控股子公司药友制药与辉瑞签订许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2590310434","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590310434?lang=zh_cn&edition=full","pubTime":"2025-12-09 19:00","pubTimestamp":1765278029,"startTime":"0","endTime":"0","summary":"此外，基于许可产品的年度净销售额达成情况，由辉瑞向药友制药依约支付至多15.85亿美元的销售里程碑款项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6692cc092fbadfcafce950a9c4d79e01","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900030616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK0175","BK0239","BK1191","01477","600196","BK0188","BK1574","BK1593","BK0028","BK0187","BK0183","BK0196","BK0012","BK0060","BK0096","02196"],"gpt_icon":0},{"id":"2589331879","title":"复星医药最新公告：公司多款药品新纳入国家医保目录及商保创新药目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589331879","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589331879?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:01","pubTimestamp":1765094463,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司多款已上市产品获首次纳入或涉及备注信息调整。其中，芦沃美替尼片、枸橼酸伏维西利胶囊、吡仑帕奈口服混悬液、盐酸替那帕诺片、普托马尼片等药品新纳入2025年国家医保目录，盐酸凯普拉生片、拓培非格司亭注射液备注信息调整，阿基仑赛注射液新纳入商保创新药目录。预计将对公司后续年度业绩产生积极影响，但具体影响尚无法确定。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120700003097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600196","BK0060","BK0175","BK0183","BK0028","BK0239","159992","BK0196","BK0012","BK1574","BK0096","06978","BK1515","BK0187","02196","BK1593","BK1161","BK1191"],"gpt_icon":0},{"id":"2588009934","title":"复星医药2025年A股股票期权激励计划首次授予完成，182名激励对象获授444.64万份期权","url":"https://stock-news.laohu8.com/highlight/detail?id=2588009934","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588009934?lang=zh_cn&edition=full","pubTime":"2025-12-04 15:36","pubTimestamp":1764833770,"startTime":"0","endTime":"0","summary":"中访网数据 上海复星医药(集团)股份有限公司于2025年12月3日发布公告，宣布其2025年A股股票期权激励计划首次授予的登记工作已完成。本次激励计划首次授予的授予日为2025年11月4日，实际向182名激励对象授予了总计4,446,400份A股股票期权，约占公司当前总股本的0.1665%。 根据激励计划安排，首次授予的A股期权将分三期行权，等待期分别为12个月、24个月和36个月。 本次股权激励产生的股份支付费用将在激励计划实施过程中分期摊销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251204/31844205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["600196","BK0060","BK1191","BK0012","BK0028","BK0188","BK0196","BK1593","BK0187","159982","399300","02196","BK0175","BK0239","BK0096","BK0183","BK1515"],"gpt_icon":0},{"id":"2588197860","title":"复星医药最新公告：控股子公司拟用于治疗晚期恶性实体瘤创新药物FXS887片获临床试验批准于全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2588197860","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588197860?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:56","pubTimestamp":1764752215,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，控股子公司上海复星医药产业发展有限公司（简称“复星医药产业”）收到国家药品监督管理局关于同意FXS887片（简称“FXS0887”）用于晚期恶性实体瘤开展临床试验的批准。FXS0887为本集团（即本公司及控股子公司/单位）自主研发的口服小分子创新药物，拟用于治疗晚期恶性实体瘤。截至本公告日期（即2025年12月3日），于全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300025352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0188","BK1593","600196","BK0012","BK0096","BK1191","BK0196","BK1515","BK1161","BK0239","06978","BK0060","BK0187","BK0183","BK0028","02196","BK1574","159992"],"gpt_icon":0},{"id":"2588067851","title":"复星医药旗下私募基金LP变更，大连金运接替大连融达成新合伙人","url":"https://stock-news.laohu8.com/highlight/detail?id=2588067851","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588067851?lang=zh_cn&edition=full","pubTime":"2025-12-03 07:58","pubTimestamp":1764719922,"startTime":"0","endTime":"0","summary":"中访网数据 上海复星医药(集团)股份有限公司于2025年12月2日发布公告，披露其参与设立的私募股权投资基金——大连星未来创业创新基金合伙企业发生有限合伙人变更。变更完成后，大连金运将持有基金29%的份额，成为新的有限合伙人。复星医药通过控股子公司大连复健和宁波复瀛合计认缴的2.55亿元出资额及51%的份额比例保持不变，基金总认缴规模仍为5亿元。大连金运由大连市财政局全资控股，与复星医药无关联关系。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251203/31839848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02196","BK0012","BK0188","600196","BK0060","BK0096","BK1515","BK0183","BK1593","BK0028","BK0239","BK1191","BK0187","BK0196","BK0175"],"gpt_icon":0},{"id":"2588805956","title":"复星医药（600196）披露选举执行董事议案获股东会通过，12月2日股价下跌0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588805956","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588805956?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:08","pubTimestamp":1764684535,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，复星医药报收于27.09元，较前一交易日下跌0.88%，最新总市值为723.42亿元。该股当日开盘27.35元，最高27.35元，最低27.0元，成交额达2.65亿元，换手率为0.46%。公司近日发布公告称，上海复星医药（集团）股份有限公司于2025年12月2日召开2025年第二次临时股东会，会议由董事会召集，董事长陈玉卿主持，采用现场与网络结合方式召开。出席会议股东共1,726人，代表有表决权股份总数1,081,006,672股，占公司总股本的40.9541%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200039334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","BK0096","BK0188","02196","BK0028","BK0060","BK1191","BK0183","BK0196","600196","BK0175","BK0187","BK1515","BK0239","BK0012"],"gpt_icon":0},{"id":"1128708003","title":"复星医药 - 含肝素钠注射液的药物申请已被NMPA接受","url":"https://stock-news.laohu8.com/highlight/detail?id=1128708003","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128708003?lang=zh_cn&edition=full","pubTime":"2025-12-02 20:46","pubTimestamp":1764679594,"startTime":"0","endTime":"0","summary":"复星医药 - 含肝素钠注射液的药物申请已被NMPA接受","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0188","BK0060","BK0096","600196","BK0183","BK0028","BK0187","BK0239","BK0196","BK0012"],"gpt_icon":0},{"id":"2588370540","title":"复星医药(02196)：刘毅获选举为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2588370540","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588370540?lang=zh_cn&edition=full","pubTime":"2025-12-02 19:47","pubTimestamp":1764676050,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，于临时股东会上，刘毅先生获股东正式选举为第十届董事会执行董事，委任自2025年12月2日起生效至本届董事会任期届满为止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0239","600196","BK1593","BK0012","BK0096","BK0175","BK0196","BK0028","BK0060","BK1515","BK0187","BK1191","02196","BK0188"],"gpt_icon":0},{"id":"2588311400","title":"复星医药子公司HLX14药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2588311400","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588311400?lang=zh_cn&edition=full","pubTime":"2025-12-02 18:10","pubTimestamp":1764670224,"startTime":"0","endTime":"0","summary":"12月2日，复星医药（600196/02196）发布公告，控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的地舒单抗生物类似药HLX14的药品注册申请已获国家药品监督管理局受理。HLX14的适应症参照已在中国境内获批上市的药品普罗力?的所有适应症。HLX14目前已在美国、欧盟和英国获批上市，2024年9月，其在加拿大的上市注册申请也已获受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023580475079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK1191","BK0028","600196","BK0239","BK0175","BK1515","02196","BK1593","BK0012","BK0187","BK0060","BK0196","BK0096","BK0183"],"gpt_icon":0},{"id":"2588803114","title":"复星医药子公司肝素钠注射液注册申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2588803114","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588803114?lang=zh_cn&edition=full","pubTime":"2025-12-02 18:06","pubTimestamp":1764669990,"startTime":"0","endTime":"0","summary":"12月2日，复星医药（600196/02196）发布公告，控股子公司药品注册申请获国家药品监督管理局受理。公告中提到，苏州二叶制药有限公司就肝素钠注射液的药品注册申请获得受理，该药品为公司自主研发的化学药品，主要用于防治静脉血栓和肺栓塞等多种医疗用途。截至2025年10月，苏州二叶在该药品上的累计研发投入约为861万元（未经审计）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023580474174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0096","BK0028","BK0012","BK0196","BK1191","BK0060","BK1593","BK1515","BK0188","02196","BK0183","BK0187","600196","BK0239","BK0175"],"gpt_icon":0},{"id":"2588728927","title":"复星医药(600196.SH)控股子公司HLX37注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588728927","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588728927?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:04","pubTimestamp":1764579890,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(合称“复宏汉霖”)收到国家药品监督管理局关于同意HLX37注射液(即重组人源化抗PD-L1与抗VEGF双特异性抗体注射液;简称“HLX37”)用于治疗晚期/转移性实体瘤患者开展临床试验的批准。复宏汉霖拟于条件具备后于中国境内开展HLX37的Ⅰ期临床试验。HLX37是集团自主研发的重组人源化抗PD-L1与抗VEGF双特异性抗体，拟用于治疗晚期/转移性实体瘤。截至目前的临床前研究表明，HLX37能够抑制肿瘤生长，且具有良好的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","BK1593","BK1191","BK0012","BK0060","BK0188","BK0239","BK0183","BK1515","BK0196","BK0028","600196","BK0187","BK0175","BK0096"],"gpt_icon":0},{"id":"2586738565","title":"复星医药（600196）披露关于召开2025年第二次临时股东会的提示性公告，11月28日股价下跌0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586738565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586738565?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:13","pubTimestamp":1764339192,"startTime":"0","endTime":"0","summary":"截至2025年11月28日收盘，复星医药报收于27.13元，较前一交易日下跌0.29%，最新总市值为724.49亿元。公司近日发布公告称，上海复星医药（集团）股份有限公司将于2025年12月2日召开2025年第二次临时股东会，会议采用现场投票和网络投票相结合的方式，审议《关于选举执行董事的议案》。股权登记日为2025年11月26日，A股股东可于当日收市后在中国证券登记结算有限责任公司上海分公司登记在册参与投票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800039578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0175","BK1593","BK0196","BK0096","BK0012","BK0188","BK0028","BK1515","02196","600196","BK0060","BK0183","BK1191","BK0239"],"gpt_icon":0},{"id":"2586474186","title":"复星医药与睿智医药达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2586474186","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586474186?lang=zh_cn&edition=full","pubTime":"2025-11-25 23:01","pubTimestamp":1764082916,"startTime":"0","endTime":"0","summary":"人民财讯11月25日电，11月25日，复星医药与睿智医药在上海举行战略合作框架协议签约仪式。复星医药高级副总裁兼全球研发中心首席执行官李翔表示，未来，借助与睿智医药全链条研发服务能力，有望进一步提升复星医药在多种类型药物研发领域的效率与质量，加速创新成果转化，巩固我们在创新医药领域的竞争优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511253574517765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","BK0183","BK0188","BK1593","600196","BK0239","BK0096","BK0028","BK0012","BK0216","BK1515","BK0187","BK1191","BK0175","300149","BK0196","BK0077","02196"],"gpt_icon":0},{"id":"2585116342","title":"复星医药(600196.SH)子公司芦沃美替尼片药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2585116342","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585116342?lang=zh_cn&edition=full","pubTime":"2025-11-21 17:25","pubTimestamp":1763717103,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复星医药产业发展有限公司就复迈宁用于治疗2岁及2岁以上朗格汉斯细胞组织细胞增生症儿童患者的药品注册申请获国家药品监督管理局受理并已被纳入优先审评程序。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK0183","BK1593","BK0175","BK0060","BK0188","BK0012","BK0196","BK0096","02196","BK1191","BK0239","BK0187","600196","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765424777493,"stockEarnings":[{"period":"1week","weight":0.047},{"period":"1month","weight":-0.0081},{"period":"3month","weight":-0.0952},{"period":"6month","weight":0.11},{"period":"1year","weight":0.0876},{"period":"ytd","weight":0.1529}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0294},{"period":"3month","weight":0.0065},{"period":"6month","weight":0.155},{"period":"1year","weight":0.1396},{"period":"ytd","weight":0.1637}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","registeredCapital":"267042万元","survey":" 上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。","listedPrice":7.15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,600196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}